Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Valeo Pharma Inc VPHIF

Healthcare
Valeo Pharma Inc. is a Canadian pharmaceutical company. The Company acquires, or in-licenses branded pharmaceuticals and hospital specialty products for sale in Canada. The Company is engaged in the commercialization of prescription products in Canada with a focus on respiratory/allergy, ophthalmology and hospital specialty products. Its respiratory/allergy products include Enerzair Breezhaler, Atectura Breezhaler and Allerject. The ophthalmology products include Xiidra and Simbrinza. Its specialty products include Redesca, Onstryv, M-Eslon, Yondelis and Ametop Gel 4%. The Company's wholly owned subsidiary is VPI Pharmaceuticals Inc.


GREY:VPHIF - Post by User

Valeo Pharma Inc > IA analist update report
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(21)
•••
Comment by eric40on Mar 30, 2021 11:32am
172 Views
Post# 32905934

RE:RE:IA analist update report

RE:RE:IA analist update reportI guess the market wonder if Valeo has enough cash runway to finance the day to day operations and the hiring and formation of nearly 40 new employees in very short term.

Steeve said that the new product from Novartis will be technically available for everyone as soon as next week and they are hiring now and formation on the new products should be done by mid may, meaning there is money to be spent by end of may.

So the question is, will there be a small financing or do they have sufficient cash runway?
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities